Phylogix Inc.
http://www.phylogix.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Phylogix Inc.
Immune Pharma names Paul Nadler CMO
Immune Pharmaceuticals has appointed Dr Paul Nadler acting executive vice-president of R&D, and chief medical officer. In this position, Dr Nadler will be responsible for overseeing the development of Immune's immunology and oncology pipeline. Dr Nadler has been an interim or acting CMO (or similar) for a variety of early stage biotechnology companies such as OSI Pharmaceuticals, Fast Track Systems, Alexion Pharmaceuticals, CGI Pharma, Phylogix, Aveo, Dicerna and others.
Pfizer Ventures co-launches $16m rare drug accelerator
A new rare disease drug accelerator has launched in the US with $16 million in financing and big plans to spin-out up to five new companies in the next four years, developing orphan-focused products.
Cydan Hopes To Accelerate Rare Disease Drug Development With $16M Raise
The Massachusetts start-up has plans to create five new companies that will focus on rare disease work through an innovative business model that will de-risk the assets before spinning them out into separate biotech companies.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice